CNTN
Canton StrategicBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The balance sheet was transformed by the November 2025 financing, 2025 year-end CC fair value was about $501.8 million, and management has paired treasury exposure with validator and governance roles that could create differentiated access if Canton adoption keeps rising [#10-K-2026-03-31].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -1.9.
What can break
Additional capital raises or ATM usage could fund strategy expansion but dilute existing holders.
Momentum
16
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.80 · Bull $5.50 · Bear $2.10
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum16 · Δ7d +5.8
Value41 · Δ7d +0.0
Sentiment100 · Δ7d -1.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
16
26% active weight
Current posture
7d trendFlat
Δ7d
+5.8
Δ21d
-6.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
100
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.9
Δ21d
-8.4
Why this grade
Composite grade B. Momentum 16.0 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$158.1M
Beta
1.43
Shares Out
77.12M
P/E (TTM) · Derived
-1.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.02
Rev YoY
-
EPS YoY
-76.9%
Gross Margin
-
Op Margin
-
Net Debt
-$17.03M
Current Ratio
37.75
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology